Phaseline

Companies › Beijing Mabworks Biotech

Beijing Mabworks Biotech: clinical trials, targets and expected readouts

5 active drug programs in 8 registered trials: 5 Phase 1, 2 Phase 3, 1 Phase 2; Oncology, Genitourinary, Neurology, Immunology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Recombinant Humanized Monoclonal Antibody MIL62 Injection
Monoclonal antibody
–Phase 3Neuromyelitis Optica Spectrum Disorder; Systemic Lupus Erythematosus; Lupus NephritisMar 2027
MBS303
T-cell bispecific antibody targeting CD19 on B cells
CD19Phase 1Non-Hodgkin's LymphomaNov 2026
Recombinant Humanized Monoclonal Antibody MIL97–Phase 1Advanced or Metastatic Solid TumorDec 2026
MBS314
asymmetric trivalent tri-specific humanized antibody
–Phase 1Relapsed or Refractory Multiple MyelomaMar 2028
MIL116
anti-APRIL monoclonal antibody
APRILPhase 1Immunoglobulin A NephropathyJun 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05796206Recombinant Humanized Monoclonal Antibody MIL62 InjectionPhase 2Systemic Lupus ErythematosusImmunologyNov 2024
NCT07044115Recombinant Humanized Monoclonal Antibody MIL62 InjectionPhase 1Lupus NephritisImmunologyJan 2025
NCT05806099MBS303Phase 1Non-Hodgkin's LymphomaOncologyNov 2026
NCT04965077Recombinant Humanized Monoclonal Antibody MIL97Phase 1Advanced or Metastatic Solid TumorOncologyDec 2026
NCT05314010Recombinant Humanized Monoclonal Antibody MIL62 InjectionPhase 3Neuromyelitis Optica Spectrum DisorderNeurologyMar 2027
NCT06232096MBS314Phase 1Relapsed or Refractory Multiple MyelomaOncologyMar 2028
NCT07375758MIL116Phase 1Immunoglobulin A NephropathyGenitourinaryJun 2028
NCT07405970Recombinant Humanized Monoclonal Antibody MIL62 InjectionPhase 3Systemic Lupus ErythematosusImmunologyDec 2028

Targets

CD19 (1) APRIL (1)

Companies with the same targets

Gilead Sciences Bristol-Myers Squibb Chongqing Precision Biotech Allogene Therapeutics Miltenyi Biomedicine Amgen AstraZeneca Beijing Yongtai Ruike Biotechnology Company Shanghai Ming Ju Biotechnology iCell Gene Therapeutics

Companies built like this

Bio-Thera Solutions Jemincare Tanabe Pharma BioRay Pharmaceutical Nanjing Sanhome Pharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.